Home / Health / New Vaccine Slashes Baby Hospitalizations
New Vaccine Slashes Baby Hospitalizations
18 Apr
Summary
- Pregnancy vaccine cuts infant hospital admissions by over 80%.
- RSV virus causes severe breathing and feeding issues in newborns.
- Vaccine offers nearly 85% protection when given four weeks prior.
A vital vaccine offered during pregnancy is proving highly effective in protecting newborns from serious chest infections, according to UK health officials. This intervention has led to a reduction of more than 80% in hospital admissions for babies suffering from RSV (respiratory syncytial virus).
Since 2024, expectant mothers have been eligible for the vaccine from the 28th week of gestation. A recent study analyzed the vaccine's impact, confirming it delivers "excellent protection" to infants when they are most susceptible to RSV, a common cause of hospitalization for babies under one year old.
The study, which monitored nearly 300,000 babies born in England between September 2024 and March 2025, found that protection is nearly 85% effective if the vaccine is administered at least four weeks before delivery. Even a two-week window offers some protection, particularly for premature births.
This development offers significant hope for safeguarding infants, especially during winter months. Health professionals strongly encourage pregnant women to discuss the RSV vaccine with their midwives and healthcare providers to ensure timely vaccination.
